Skip to search formSkip to main contentSkip to account menu

CI 960

Known as: CI-960 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

clinafloxacin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2003
Review
2003
Novel FLT3 point mutation in acute myeloid leukaemia.
1996
1996
The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects.
The single-dose tolerance and pharmacokinetics of clinafloxacin, a new fluoroquinolone antibacterial agent, were evaluated in… 
1995
1995
Activity of CI-960 alone and in combination with amoxycillin against Listeria monocytogenes, and comparison with other quinolones.
In-vitro activity of CI-960 against seven strains of Listeria monocytogenes was compared to that of other fluoroquinolones. MICs… 
1994
1994
Bactericidal activities of DU-6859a and clinafloxacin (CI-960) against staphylococci
Time killing curves were calculated at concentrations of 2 and 8 times the MICs of DU-6859a and clinafloxacin against six… 
1993
1993
In vitro investigation of the intraphagocytic bioactivities of ciprofloxacin and the new fluoroquinolone agents, clinafloxacin (CI-960) and PD 131628.
In this study the intraphagocytic bioactivities of the new fluoroquinolone antimicrobial agents clinafloxacin (CI-960) and PD… 
Review
1993
Review
1993
Patterns of susceptibility to fluoroquinolones among anaerobic bacterial isolates in the United States.
The activity of the fluoroquinolone antibiotics against anaerobic bacteria has generally been moderate to poor. Nalidixic acid… 
1993
1993
Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin.
The susceptibility of anaerobic bacteria to two new fluoroquinolones, PD 131628 (the bioactive form of PD 131112 or CI-990) and… 
1992
1992
Postantibiotic effect of CI-960, enoxacin and ciprofloxacin on Escherichia coli: effect on morphology and haemolysin activity.
The postantibiotic effect (PAE) has been classically defined as the suppression of bacterial growth that persists after limited… 
1992
1992
CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis
CI-960 is a new fluoroquinolone with enhanced in vitro activity against gram-positive pathogens. The efficacy of the drug was… 
1991
1991
Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)